Home > Insider Trading > Filing (0001070081-18-000018)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578850	Gregory Neil Almstead	C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080	Evp Research Pharma Ops & Tech	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-03	874	$0.00	5,284	No	4	A	Indirect	By spouse
Common Stock	Disposition	2018-01-04	77	$17.67	5,207	No	4	S	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Indirect	By spouse
No	4	S	Indirect	By spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right To Buy)	Acquisiton	2018-01-03	70,000	$0.00	70,000	$18.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,000		2028-01-02	No	4	A	Direct

Footnotes

Restricted stock unit (RSU) award vests in four equal annual installments over four years, commencing on January 3, 2019. Upon vesting, each RSU will convert into one share of the issuer.
Includes 1,060 shares acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2017 and 663 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2017.
Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 180 RSUs from a January 3, 2017 grant of 720 shares.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.